IMRX 8-K: Press Release Furnished for Quarter Ended June 30, 2025

Rhea-AI Filing Summary

Immuneering Corporation announced its financial results for the quarter ended June 30, 2025 and provided operational updates, and the company furnished the full press release as Exhibit 99.1 to this Current Report. The 8-K itself does not contain the detailed financial figures or operational text; those details are included in the attached press release.

The filing explicitly states that the information is furnished, not filed, meaning it is not subject to Section 18 liabilities of the Exchange Act and is not incorporated by reference into other filings except by specific reference. This document serves as a formal vehicle to make the quarter-end results and operational commentary publicly available, while the substantive metrics and narrative are contained in the exhibit.

Insights

Financial Analyst

TL;DR: Routine earnings announcement furnished without figures; investors must review Exhibit 99.1 for material metrics.

The 8-K notifies the market that Immuneering reported results for the quarter ended June 30, 2025 and furnished a press release as Exhibit 99.1. Because the filing does not include revenue, profit, cash balance, or guidance figures, the 8-K alone does not enable assessment of financial performance or trend analysis. The press release exhibit is the primary source for material metrics; the 8-K’s "furnished, not filed" status limits statutory liability but preserves public disclosure obligations.

Corporate Governance Expert

TL;DR: Disclosure reflects standard compliance practice; the "furnished" designation limits legal exposure while ensuring public access to the release.

This Current Report follows typical disclosure protocol by furnishing a press release and noting it is not "filed" under the Exchange Act. That distinction is important from a governance and disclosure-liability perspective: it provides transparency to the market while limiting the registrant’s Section 18 exposure. The document includes the CEO’s signature block, evidencing authorized corporate attestation of the disclosure process.

0001790340FALSE00017903402025-08-132025-08-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

__________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2025

__________________________________

Immuneering Corporation

(Exact name of Registrant as Specified in Its Charter)

__________________________________

Delaware			001-40675			26-1976972
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)

245 Main St.

Second Floor

Cambridge, MA 02142

(Address of principal executive offices) (Zip Code)

(617) 500-8080

(Registrant’s telephone number, include area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A common stock, par value $0.001 per share

IMRX

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 13, 2025, Immuneering Corporation (the “Company”) announced its financial results for the quarter ended June 30, 2025 and provided operational updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Current Report”).

The information in this Item 2.02 of this Current Report, including Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits

The following exhibits relate to Item 2.02, which shall be deemed to be furnished, and not filed:

Exhibit No.						Description
99.1						Press Release issued on August 13, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			IMMUNEERING CORPORATION
Date: August 13, 2025			By:			/s/ Benjamin J. Zeskind
						Name: Benjamin J. Zeskind, Ph.D.
						Title: Co-Founder, President, Chief Executive Officer and Director (Principal Executive Officer)